Amylyx Pharmaceuticals Inc expected to post a loss of 52 cents a share - Earnings Preview

Amylyx Pharmaceuticals

28/02/2025 13:42

Amylyx Pharmaceuticals Inc AMLX.OQ AMLX.O is expected to show a fall in quarterly revenue when it reports  results on March 4 for the period ending December 31 2024

​LSEG's mean analyst estimate for Amylyx Pharmaceuticals Inc is for a loss of 52 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Amylyx Pharmaceuticals Inc is $10.00​, above​ its last closing price of $3.16. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.75
-0.71
-1.07
Missed
-50.7
Jun. 30 2024
-0.64
-0.73
-0.73
Met
0
Mar. 31 2024
0.02
-0.01
-0.12
Missed
-1,900​
Dec. 31 2023
0.24
0.23
0.07
Missed
-69.3
​​Sep. 30 2023
0.43
0.44
0.30
Missed
-31
Jun. 30 2023
0.08
0.10
0.31
Beat
210​
Mar. 31 2023
-0.23
-0.24
0.02
Beat
108.3
Dec. 31 2022
-0.82
-0.82
-0.65
Beat
20.7

This summary was machine generated February 28 at 13:42 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)